Big pharma's pre-competitive collaboration


Big pharma's pre-competitive collaboration

Handshaking Image showing gesture of collaboration between two firms

Merck, Eli Lilly and Pfizer have provided funding to launch Enlight Biosciences, a for-profit venture that aims to advance breakthrough technologies for drug discovery and development.


The lowdown: There has recently been increasing emphasis from industry on participating in non-profit collaborations to address issues in drug development that are considered to be pre-competitive. 

Now, Merck, Eli Lilly and Pfizer, together with the venture capital firm PureTech Ventures and several leading academic researchers, have founded Enlight Biosciences. 


This is a for-profit venture that will aim to tackle critical unmet industry needs with innovations from academia and start-up companies. Enlight Biosciences, based in Boston, USA, will direct up to US$39 million into technologies that strengthen the connection between preclinical research, clinical research and post-market use, such as techniques that could help predict human responses to experimental therapies.


Comments

Popular posts from this blog

 Role of Blockchain in Healthcare Data Management

Demystifying AI in Drug Discovery: Transforming Pharma R&D

GREEN INITIATIVES IN INDIA : Sustainable Practices in Pharmaceuticals